RxDoctor Payments Data

Perry Carlos, DO

Family Medicine · Jacksonville, FLNPI 1801873443

Payments from drug & device makers

$12,741in general payments, 2019–2025

Across 831 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$909
  • Boehringer Ingelheim$844
  • Lilly USA, LLC$809
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$12,718100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,741 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$181,820
Medicare patients
486
Services billed
3,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$125,485
OzempicSemaglutide71$76,284
JardianceEmpagliflozin48$53,090
XareltoRivaroxaban27$38,267
TrulicityDulaglutide34$36,296
MounjaroTirzepatide33$34,277
JanuviaSitagliptin Phosphate18$17,731
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,079
Repatha SureclickEvolocumab12$9,854
EntrestoSacubitril/Valsartan15$9,659
VascepaIcosapent Ethyl13$9,365
SymbicortBudesonide/Formoterol Fumarate29$8,031
Breo ElliptaFluticasone/Vilanterol16$7,741
Omeprazole275$5,342
Gabapentin188$5,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,271$125,485105 claims
Novo NordiskOzempic$1,208$76,28471 claims
Lilly USA, LLCTrulicity, Mounjaro$809$70,57367 claims
Boehringer IngelheimJardiance$844$53,09048 claims
Johnson & JohnsonXarelto$340$38,26727 claims
GSKTrelegy Ellipta, Breo Ellipta$744$18,82031 claims
MerckJanuvia$696$17,73118 claims
NovartisEntresto$54$9,65915 claims
AstraZenecaSymbicort$909$8,03129 claims
AbbVieSynthroid$1,078$4,75145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →